United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE

The U.S. became the fifth nation behind the U.K., Bahrain, Canada and Saudi Arabia to approve a coronavirus vaccine candidate for emergency use. The verdict from the drug regulator came swifter than even the rapid timeline expected by many.

Pfizer-BioNTech Gets FDA Nod For Emergency Use Of Coronavirus Vaccine; Deliveries To Begin Immediately

Albert Bourla and his team overcame unproven science and manufacturing bottlenecks; ‘you're asking for too much.'.

How Pfizer delivered a COVID vaccine in record time: Crazy deadlines, a pushy CEO

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration (FDA) has authorized the emergency use of the mRNA vaccine, BNT162b2, against COVID-19 in individuals 16 years of age or older. The vaccine is now authorized under an Emergency Use Authorization (EUA) while Pfizer and BioNTech gather additional data and prepare to file a planned Biologics License Application (BLA) with the FDA for a possib

Pfizer and BioNTech Celebrate Historic First Authorization in the U.S. of Vaccine to Prevent COVID-19

Vaccinations could start as soon as next week.

FDA authorizes Pfizer's COVID-19 vaccine for emergency use

The Food and Drug Administration authorized BioNTech and Pfizer Inc.'s COVID-19 vaccine Friday evening, which will make it the first vaccine for the coronavirus to reach Americans during the public-health crisis.

First COVID-19 vaccine receives emergency approval in U.S.

The Food and Drug Administration gave emergency use authorization for the first time to a coronavirus vaccine, a milestone in the fight against the pandemic that has resulted in the deaths of almost 100,000 Americans. “Today's action follows an open and transparent review process that included input from independent scientific and public health experts and...

FDA Authorizes Emergency Use Of Pfizer's Coronavirus Vaccine

The U.S. Food and Drug Administration (FDA) has granted an Emergency Use Authorization (EUA) for the COVID-19 vaccine developed by Pfizer and its partner BioNTech, the New York Times first reported on Friday night, and later supported by The Wall Street Journal. This EUA follows a recommendation by an independent panel of experts commissioned by the […]

FDA grants emergency use authorization for Pfizer's COVID-19 vaccine, distribution to begin within days

The FDA has approved Pfizer and BioNTech's coronavirus vaccine for emergency use, a monumental turning point in the once-in-a-century pandemic.

FDA approves Pfizer's Covid vaccine for emergency use as U.S. reaches pivotal moment in the pandemic

US regulators have authorized the first coronavirus vaccine for emergency use, marking an inflection point in the pandemic and kicking off what's set to be the largest vaccination campaign in US history. The US Food and Drug Administration OK'd a highly effective COVID-19 vaccine developed by the drugmakers Pfizer and BioNTech, FDA said in a letter on its website. The decision followed an endorsement from an independent expert panel that reviewed data on the shot.

PFIZER SHOT GETS OK: US regulators greenlight first coronavirus vaccine for emergency use

Dr. Archana Chatterjee, dean of the Chicago Medical School, who was one of the four FDA panel “no” votes, explains her decision.

FDA advisor who voted against recommending Pfizer's Covid vaccine explains why she would ‘be first in line' to get it

There is "no known or expected causal relationship between the vaccine and Bell's palsy," the Centers for Disease Control and Prevention said Friday.

CDC will monitor for Bell's palsy among Pfizer vaccine recipients, but sees no causal relationship

The US government is expected to approve the Pfizer COVID-19 vaccine for emergency use within hours, according to reports.

US closer to approving Pfizer coronavirus vaccine for emergency use

Pfizer Inc. (NYSE: PFE) and BioNTech SE's – ADR (NASDAQ: BNTX) coronavirus vaccine candidate passed the Adcom test, with the FDA panel voting 17-4 in favor of its risk-benefit profile in individuals 16 and older.  Here's SVB Leerink analyst Geoffrey Porges' take on the dynamics of the Adcom vote.

Pfizer Analyst Breaks Down The FDA Process For Coronavirus Vaccine Candidate

White House chief of staff Mark Meadows told the head of the FDA to submit his resignation if the agency doesn't clear Pfizer's vaccine for emergency use by day's end, according to reports.

White House threatens to fire FDA chief unless Pfizer Covid vaccine approved Friday, report says

Moderna

Moderna is next in line to win FDA approval for its COVID-19 vaccine.

FDA's Pfizer COVID vaccine approval means Moderna's just days away

Hello, What a week it's been. If you had any doubts this month could be one long marathon of vaccine news, this week certainly proved the case.

The FDA is preparing to authorize Pfizer's vaccine

Food and Drug Administration Commissioner Stephen Hahn said the agency would "rapidly" authorize Pfizer and BioNTech's coronavirus vaccine — but Pfizer stock fell early Friday. The post FDA Says It Will 'Rapidly' Authorize Pfizer's Covid Vaccine; But Shares Fall appeared first on Investor's Business Daily.

FDA Says It Will 'Rapidly' Authorize Pfizer's Covid Vaccine; But Shares Fall

An FDA panel recommends granting approval for emergency use of Pfizer's (PFE)/BioNTech's (BNTX) COVID-19 vaccine

Pfizer/BioNTech COVID-19 Vaccine Gets FDA Panel's Backing

The imminent authorization of Pfizer's Covid-19 vaccine in the United States is a momentous occasion for science, the economy and humanity. The milestone is also a major moneymaker for the companies that developed the vaccines.

Pfizer and Moderna could score $32 billion in Covid-19 vaccine sales -- in 2021 alone

Alex Azar said the government is on “just the last dotting of i's and crossing of t's” before it approves the first vaccine.

Covid-19 Vaccinations Could Start ‘Monday Or Tuesday' As FDA Set To Approve Pfizer Vaccine, HHS Chief Says

In a historic development, an FDA committee overwhelmingly voted in favor Thursday of the agency approving BNT162b2, an mRNA vaccine being developed by Pfizer Inc. (NYSE: PFE) and BioNTech SE – ADR (NASDAQ: BNTX) against the coronavirus.  What Happened: FDA has informed Pfizer that the agency is rapidly working toward finalization and issuance of an emergency use authorization for its co-developed investigational vaccine, FDA Commissioner Stephen Hahn said in a Friday statement.

FDA 'Rapidly Working' On Emergency Use Authorization For Pfizer, BioNTech's Coronavirus Vaccine

Pfizer gained as much as 2.2% in early Friday trading after a panel of experts recommended that the US Food and Drug Administration approve its coronavirus vaccine for emergency use. The group, which included infectious disease experts, statisticians, and public health scientists, voted 17 to 4 on Thursday in favor of authorizing the shot for people at least 16 years old. One member abstained.

Pfizer climbs 2% as FDA nears final authorization of its COVID-19 vaccine

Here's what you need to know about the impact of Covid-19 to navigate the markets today.

Pfizer's Vaccine Will Be Authorized for Emergency Use, Azar Says

The Food and Drug Administration will grant emergency-use authorization for the COVID-19 vaccine developed by Pfizer and BioNTech, Health and Human Services Secretary Alex Azar said Friday.

Pfizer coronavirus vaccine to receive FDA emergency-use authorization: Alex Azar

Dr. Archana Chatterjee told CNBC on Friday she's "fully supportive" of emergency use authorization for people who are 18 years and older.

News for Pfizer Stock (PFE)